Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Raffaele De Caterina, Walter Ageno, Giuseppe Boriani, Paolo Colonna, Angelo Ghirarduzzi, Giuseppe Patti, Roberta Rossini, Andrea Rubboli, Piercarla Schinco, Giancarlo Agnelli

Research output: Contribution to journalArticlepeer-review

Abstract

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - Feb 13 2017
Externally publishedYes

Keywords

  • Atrial fibrillation
  • Edoxaban
  • Non-vitamin K antagonist oral anticoagulants
  • Oral anticoagulants
  • Venous thromboembolism
  • Vitamin K antagonists

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide'. Together they form a unique fingerprint.

Cite this